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Abstract
Background. Heart rate variability (HRV), a noninvasive
measure of autonomic dysfunction and a risk factor for
cardiovascular disease (CVD), has not been systematically
studied in nondialysis chronic kidney disease (CKD).
Methods. HRV was assessed using 24-h Holter monitor-
ing in 305 subjects from the Renal Research Institute-
CKD Study, a four-center prospective cohort of CKD
(Stages 3–5). Multiple linear regression was used to as-
sess predictors of HRV (both time and frequency domain)
and Cox regression used to predict outcomes of CVD,
composite of CVD/death and end-stage renal disease
(ESRD).
Results. A total of 47 CVD, 67 ESRD and 24 death events
occurred over a median follow-up of 2.7 years. Lower HRV
was significantly associated with older age, female gender,
diabetes, higher heart rate, C-reactive protein and phospho-
rus, lower serum albumin and Stage 5 CKD. Lower HRV
(mostly frequency domain) was significantly associated with
higher risk of CVD and the composite end point of CVD or
death. Significantly, lower HRV (frequency domain) was
associated with higher risk of progression to ESRD,
although this effect was relatively weaker.
Conclusions. This study draws attention to the importance
of HRV as a relatively under recognized predictor of adverse
cardiovascular and renal outcomes in patients with nondial-
ysis CKD. Whether interventions that improve HRV will
improve these outcomes in this high-risk population
deserves further study.
Keywords: autonomic nervous system; cardiovascular disease risk
factors; cardiovascular outcomes; cohort study; end-stage renal disease
Introduction
Increased cardiovascular (CV) morbidity and mortality is
well documented in chronic kidney disease (CKD) [1].
Sudden cardiac death accounts for about a third of total
mortality among dialysis patients, that could in part, be
due to autonomic nervous system (ANS) dysfunction [2]
and increased sympathetic activity, in particular [3]. Increased
sympathetic activity is also noted in patients with CKD [4]
and likely contributes to the higher risk of cardiovascular
disease (CVD) and also renal damage.
Heart rate variability (HRV) is a noninvasive measure of
autonomic function that reflects beat-to-beat variability in
heart rate. It is best assessed by continuous electrocardiog-
raphy over a 24-h period, although shorter recordings have
also been utilized. It is quantified by ‘time domain’ or
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‘frequency domain’ measures. Time domain measures assess
the variability in the individual’s RR interval. For frequency
domain analysis, cyclical changes in heart rate are trans-
formed by fast Fourier transformation into a spectral repre-
sentation, which plots magnitude against frequency of these
cyclical changes [5–7]. HRV is influenced by age, race,
gender, blood pressure and certain lifestyle factors [8, 9]. It
declines after myocardial infarction (MI) and is lower among
those with coronary artery disease (CAD) and diabetes mel-
litus (DM) [10, 11]. Lower HRV has been associated with
adverse CVD outcomes in settings such as post-MI, CAD,
congestive heart failure (CHF), DM [5–7] and end-stage
renal disease (ESRD) [12, 13]. However, it has not been
systematically studied in the nondialysis CKD population.
Our study aims were to explore the distribution of sev-
eral HRV parameters across CKD Stages 3–5, investigate
important predictors of HRV and examine independent
associations of HRV with the outcomes of CVD, progres-
sion to ESRD and mortality, in a multicenter cohort of
CKD patients.
Materials and methods
The Renal Research Institute (RRI)-CKD Study is a four-center prospec-
tive cohort study of adults with moderate to severe CKD (Stages 3–5),
enrolled between June 2000 and February 2006 (n ¼ 834). The study
methodology has been published previously [14]. Eligibility criteria in-
cluded age 18 years and estimated glomerular filtration rate (eGFR) 50
mL/min by the Cockroft–Gault formula. Subsequently, the abbreviated
(four-variable) Modification of Diet in Renal Disease (MDRD) equation
was used and eGFR was between 50 and 60 mL/min/1.73m2 in 13 sub-
jects. To exclude patients with transient renal impairment prior to enroll-
ment, glomerular filtration rate (GFR) was estimated on two occasions at
least 1 month apart. At enrollment and follow-up visits, data on demo-
graphic characteristics, anthropometric measures, cause of CKD, symp-
toms, laboratory values and medications were collected.
From 1 January 2003 onwards, individuals from the original RRI-CKD
cohort (n ¼ 627) were invited to undergo noninvasive CV studies, includ-
ing 24-h Holter monitoring as part of a CV substudy. Figure 1 displays
patient recruitment flow into this CV substudy. Of the 408 patients still
alive and active at this time from the RRI-CKD study, 149 (37%) were
consented into the new CV substudy. Those who consented were signifi-
cantly healthier than those who did not: they were younger (mean age 58
versus 64), had higher mean eGFR (27 versus 25) and fewer had diabetes
(30 versus 42%) or a history of CVD (37 versus 58%). An additional 199
patients were newly recruited into this CV substudy from the renal clinics
at the four participating centers. Compared to the 149 consenters from the
original cohort, the 199 newly recruited patients were similar with respect
to age, diabetes, hypertension, history of CVD, race, gender and medica-
tion use but had significantly higher mean eGFR (32 versus 24). Finally, of
the total 348 patients consented into the CV substudy, 43 patients declined
Holter monitoring. Except for significantly older mean age (67 versus 60),
these patients were otherwise similar compared to the 305 who underwent
the procedure. A subset of the 305 patients who underwent Holter mon-
itoring also had echocardiographic data (n ¼ 204). Study coordinators at
each site were trained in Holter monitoring and other study procedures at
the University of Michigan data coordinating center to ensure uniformity of
technique and compliance with the study’s manual of operations. During
the 24-h Holter, patients went about their usual activities but were asked to
refrain from heavy physical activity. The Holter data were transferred
electronically via a file transfer protocol to the data coordinating center
where HRV was analyzed using SyneTec Holter analysis software, version
1.20 (Ela Medical, Paris, France) under the supervision of the study car-
diologist (S.R.). The 24-h tracing was examined and masking was used to
exclude areas of artifact. Abnormal atrial and ventricular rhythms were
manually verified. Time and frequency domain measures were calculated
for the 24-h period, day (8 a.m.–9 p.m.) and nighttime periods. The termi-
nology/abbreviations pertaining to the HRV parameters collected in this
study are shown in Table 1. Patients on nitroglycerin patch, with defibril-
lator, active pacing or with allergy to electrode adhesive material were
excluded.
The outcomes studied were CVD, composite of CVD/death and
ESRD (dialysis or preemptive kidney transplant). CVD events included
those related to CAD, cerebrovascular disease, peripheral arterial dis-
ease, CHF and cardiac arrest. ESRD was defined by documented initia-
tion of dialysis or preemptive renal transplantation. All outcomes were
ascertained on an ongoing basis by study coordinators from regular re-
view of electronic health records, direct patient contact in clinic and
periodic telephone communication. CVD events to be collected were
prespecified and identified using a CVD event data collection form.
Follow-up of patients ended on 31 December 2006. To compare HRV
in CKD patients with HRV in the general population, we used published
data on healthy controls [10]. The study protocol was approved by the
Institutional Review Boards of participating centers and written informed
consent was obtained from all study subjects.
Statistical analysis
Multiple linear regression models were used to investigate determinants of
the HRV parameters that were most predictive of CVD events, CVD/death
and/or ESRD. All variables from Table 2 including demographics, medical
history, laboratory values and medications were included in the multivari-
able model selection. Cox regression was used to analyze time to event
outcomes. The method of best subsets with the R-squared selection crite-
rion was used to guide the model selection process [15]. Since the inclu-
sion of left ventricular mass index (LVMI) in the model selection restricted
the sample size, model selection was performed with and without LVMI.
Comparisons of HRV parameters between this CKD cohort and the gen-
eral North American population were made using summary statistics from
published literature, using t-tests for unequal variance. All analyses were
conducted using SAS, version 9.2 (SAS Institute Inc., Cary, NC).
Results
Baseline patient characteristics
Baseline (at the time of the Holter) patient characteristics
by CKD stage are displayed in Table 2. The average age
was 59.5  14.7 years, 51% were male, 78% white and
18% black. A majority were hypertensive (89%), 31% were
diabetic and 37% had a history of CVD.
Fig. 1. Patient recruitment flow into the CV substudy of the RRI-CKD
study (n ¼ 305).
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HRV measurements
HRV measures by CKD stage are presented in Table 3. The
majority of the HRV measures were significantly lower in
diabetics compared to nondiabetics (data not shown).
Although some HRV measures significantly differed across
CKD stage, this difference was most notable in CKD Stage 5
(i.e. eGFR <15) compared with Stages 3 and 4 (i.e. eGFR
15). In univariate analysis, several HRV measures (SDNN,
SDANN, VLF and LF/HF) were significantly lower in pa-
tients with eGFR <15 mL/min/1.73m2 compared to those
with eGFR 15 mL/min/1.73m2 (Table 3).
Crude comparisons of HRV frequency (VLF, LF, HF,
LF/HF) and time (SDNN) domain parameters between the
RRI-CKD cohort and healthy population from the litera-
ture [10] are shown in Figure 2. All frequency domain and
most time domain measures in the RRI-CKD cohort were
significantly lower than healthy controls (Supplementary
Table A).
Associations of HRV with baseline clinical
characteristics
Table 4 shows associations of HRV with certain patient
characteristics. HRV measures were lower in older patients,
women, nonwhites, diabetics, those with a higher mean 24-
h heart rate, higher LVMI, elevated serum phosphorus,
higher C-reactive protein (CRP), higher high-density lip-
oprotein (HDL), lower albumin, higher urine albumin/cre-
atinine ratio (ACR), among those with an eGFR <15 mL/
min/1.73m2 and in those prescribed beta-blockers.
Association of HRV with clinical outcomes
Patients that had undergone HRV measurements had a me-
dian follow-up of 2.7 years. During this time, 47 (15%) had
at least one CVD event, 67 (22%) reached ESRD and 24
(8%) patients died. Supplementary Table B presents the
types of clinical events and major outcomes during the
follow-up period. Frequency domain measures of HRV
(LF, LF/HF, VLF and TP) were the most predictive of
outcomes. Among the time domain measures, higher
ASDNN was associated with lower risk of CVD and
CVD/death outcomes but not progression to ESRD. Sup-
plementary Table C displays the 24-h, day and night HRV
measures as predictors of CVD/death and ESRD, while
Figure 3 displays 24-h, day and night HRV measures for
CVD events. For the purposes of this study, we focused
only on the 24-h HRV measures.
The relative risk of time to first CVD event was signifi-
cantly higher with older age, history of CVD, higher phos-
phorus and lower serum albumin [Table 5(IA)]. Measures
of HRV were added one at a time to this ‘base’ model.
Higher HRV was significantly associated with a lower risk
of CVD [Figure 3 and Table 5(IIA)]. The probability of
CVD events by LF/HF ratio (dichotomized at the median)
is shown in Figure 4.
Table 5(IB) shows the base model predicting time to
the composite endpoint of CVD/death. The risk was sig-
nificantly higher with older age, history of CVD, diabetes
and lower albumin. After inclusion of HRV measures to
this model, several HRV measures were strongly predic-
tive of the composite event with higher values of HRV
associated with lower risk of the composite outcome
[Table 5(IIB)].
Table 5IC shows the time to ESRD base model, which
includes age, gender, baseline eGFR, urine ACR, LVMI
and hemoglobin. Because ACR was strongly correlated
with serum albumin (r ¼ –0.38; P < 0.0001), models with
serum albumin instead of ACR provided similar fit. After
including HRV measures to this model, higher 24-h LF/HF
ratio was the only 24-h HRV measure significantly associ-
ated with lower risk of ESRD [Table 5(IIC)]. When LVMI
Table 1. Overview of HRV parametersa
Frequency domain HRV measures Unit Description
VLF Power in very low frequency range ms2 Physiological correlate unclear; may reflect vasomotor
function, RAS and/or parasympathetic influence.
LF Power in low frequency range ms2 Reflects sympathetic or sympathetic
parasympathetic influence.
HF Power in high frequency range ms2 Reflects short-term heart rate variations, under
parasympathetic influence.
LF/HF Ratio of low to high frequency power n/a Reflects sympathovagal balance.
TP Total power ms2 Estimate of overall HRV.
Time domain HRV measures Unit Description
SDNN SD of all normal R–R (NN) intervals ms Estimate of overall HRV. When measured over 24 h,
it reflects both long- and
short-term fluctuations in HRV over 24-h period.
SDANN SD of the averages of 5-min
NN intervals over 24 h
ms Estimate of long-term components of HRV
(i.e. changes in heart
rate due to cycles >5 min).
ASDNN Average of all 5-min SDNN over 24 h
(aka SDNN index)
ms Estimate of short-term components of HRV
(i.e. changes in heart
rate due to cycles <5 min).
rMSSD The square root of the mean of the
square of successive NN intervals
ms Estimate of short-term variations in heart
rate. Reflects high frequency
variations and parasympathetic influence.
aReferences: [5, 6].
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was excluded from the model, HRV was no longer signifi-
cantly associated with ESRD (data not shown).
Discussion
To the best of our knowledge, this study represents the
first detailed analysis of HRV obtained by 24-h Holter
monitoring in a fairly large prospective cohort of referred
nondialysis CKD (Stages 3–5) patients. Lower HRV was
significantly associated with several traditional and non-
traditional risk factors for CVD including diabetes, lower
albumin, higher phosphorus, higher CRP, higher ACR
and eGFR <15 mL/min/1.73m2. Lower HRV was inde-
pendently associated with higher risk of CVD events,
composite of CVD/death and ESRD. In general, fre-
quency domain measures of HRV demonstrated greater
prognostic significance compared with time domain
measures.
Determinants of HRV in CKD
Older age, female gender and diabetes were strongly asso-
ciated with lower HRV. We found an inverse relationship




30  eGFR < 60
(n ¼ 126)
CKD Stage 4






Age 59.5 6 14.7 61.7 6 14.4 58.9 6 14.7 54.8 6 14.7
Gender
Male 50.5% (154) 46.8% (59) 54.3% (76) 48.7% (19)
Race
White 78.4% (239) 73.8% (93) 83.6% (117) 74.4% (29)
Black 17.7% (54) 23.0% (29) 12.1% (17) 20.5% (8)
Other 3.9% (12) 3.2% (4) 4.3% (6) 5.1% (2)
Body mass index (kg/m2) 29.3 6 6.7 28.7 6 6.1 29.3 6 6.3 31.1 6 9.1
Smoker 11.5% (35) 11.1% (14) 12.1% (17) 10.3% (4)
CV indices
Systolic blood pressure (mmHg) 138.9 6 23.4 140.8 6 21.2 137.2 6 24.5 138.6 6 26.4
Diastolic blood pressure (mmHg) 78.6 6 12.9 79.1 6 11.9 78.2 6 13.7 77.9 6 12.9
LVMI (g/m2) 109.7 6 36.8 106.8 6 32.9 108.2 6 36.7 119.4 6 43.1
Comorbidities
Diabetes 30.8% (94) 27.8% (35) 30.7% (43) 41.0% (16)
Hypertension 88.9% (271) 84.9% (107) 90.0% (126) 97.4% (38)
CVD 36.7% (112) 40.5% (51) 33.6% (47) 35.9% (14)
Cause of CKDc
Diabetes 25.9% (79) 23.8% (30) 24.3% (34) 38.5% (15)
Hypertension 47.9% (146) 50.0% (63) 47.1% (66) 43.6% (17)
Other 57.0% (174) 54.8% (69) 60.7% (85) 51.3% (20)
Medications
Diuretics 50.2% (153) 44.4% (56) 51.4% (72) 64.1% (25)
ACE inhibitors 46.9% (143) 45.2% (57) 47.9% (67) 48.7% (19)
A-II receptor blockers 30.8% (94) 33.3% (42) 31.4% (44) 20.5% (8)
Beta-blocker 51.1% (156) 47.6% (60) 52.9% (74) 56.4% (22)
Calcium channel blocker 42.3% (129) 40.5% (51) 42.9% (60) 46.2% (18)
Erythropoiesis-stimulating agents 24.3% (74) 17.5% (22) 22.9% (32) 51.3% (20)
Statin 48.2% (147) 48.4% (61) 50.0% (70) 41.0% (16)
Laboratory values
CRP (mg/L) 2.5 (0, 94) 2.5 (0, 49.9) 2.6 (0.1, 94.4) 1.5 (0, 35.3)
Intact parathyroid hormone (pg/mL) 114.0 (5, 1150) 93.0 (6, 991) 122.0 (5, 534) 324 (5, 1,150)
eGFR (mL/min/1.73m2) 28.2 6 11.5 39.4 6 7.2 22.7 6 4.4 11.7 6 2.3
Serum creatinine (mg/dL) 2.4 (1, 11) 1.7 (1, 2.9) 2.8 (1.8, 5) 4.9 (3.4, 10.5)
Serum albumin (g/dL) 4.0 6 0.5 4.0 6 0.4 4.0 6 0.5 4.0 6 0.4
Blood urea nitrogen (mg/dL) 37.5 (14, 131) 28.0 (14, 90) 41.0 (15, 116) 70.5 (29, 131)
Serum corrected calcium (mg/dL) 9.2 6 0.6 9.2 6 0.6 9.2 6 0.6 9.2 6 0.8
Serum glucose (mg/dL) 97.0 (46, 393) 98.0 (55, 312) 96.0 (57, 393) 103.0 (46, 361)
Serum phosphorus (mg/dL) 3.7 6 0.9 3.5 6 0.6 3.7 6 0.8 4.9 6 1.1
Serum potassium (mEq/L) 4.5 6 0.6 4.4 6 0.6 4.6 6 0.6 4.6 6 0.6
Hemoglobin (g/dL) 12.1 6 1.6 12.2 6 1.7 12.2 6 1.5 11.6 6 1.5
Total cholesterol (mg/dL) 191.9 6 51.2 195.5 6 53.0 189.3 6 49.2 189.4 6 52.8
Low-density lipoprotein (mg/dL) 109.0 6 39.7 111.8 6 41.9 106.7 6 37.6 108.0 6 40.5
High-density lipoprotein (mg/dL) 42.6 6 14.5 44.5 6 15.5 41.7 6 13.5 39.7 6 13.7
Triglycerides (mg/dL) 150.3 6 90.6 151.6 6 92.1 153.3 6 96.2 134.7 6 58.8
Urine albumin/creatinine ratio 192.0 (2, 9259) 81.2 (2, 5012.9) 243.5 (3, 9258.7) 465 (2, 5738.5)
aContinuous variables are reported as mean 6 SD for normally distributed variables and as median (min, max) for skewed variables. Significant
differences among CKD stages are shown in bold (P < 0.05).
bBased on ANOVA.
cMultiple causes of CKD are possible.
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between CRP and HRV; CRP is a known risk factor for
CVD and autonomic dysregulation may be worse among
those with inflammation [16, 17]. Similarly, serum phos-
phorus was also inversely associated with HRV. Higher
phosphorus is associated with increased CVD mortality
in patients on dialysis [18] and CKD [19]. We also found
that HRV was inversely associated with LVMI, as has also
been noted in the literature [20]. Medications had variable
associations with HRV in this cohort. Those on beta-
blockers had lower HRV, despite adjustment for history
of CAD and CHF. Beta-blockers have previously been
shown to be associated with improved HRV in settings
such as CHF [21] and acute MI [22]. We believe that the
observed association of lower HRV with medications in
our study very likely represents confounding by indication,
as these medications are preferentially used in sicker pa-
tients who tend to have lower HRV. No association was
observed between angiotensin converting enzyme inhibi-
tors or angiotensin II receptor blocker use and HRV. Drugs
that decrease sympathetic activity including alpha- and
beta-blocking agents, central sympatholytic agents, ACE
and ARBs have been shown to improve HRV in non-
CKD populations. The effect of these drugs on sympathetic
activity has also been studied in patients with kidney dis-
ease as reviewed by Kooman et al. [4]. Further studies are
clearly needed to explore the potentially beneficial effect of
these and possibly other agents (e.g. aldosterone antago-
nists) in improving HRV in patients with CKD. The asso-
ciation of higher HDL with lower HRV in this cohort is
contrary to what has been observed in the general
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Heart rate (obtained during Holter monitoring)
Mean 24-h (b.p.m.) 73.5 6 10.4 73.6 6 10.6 73.5 6 10.0 73.1 6 11.6
Mean day/night difference 7.9 6 9.7 8.0 6 8.0 8.3 6 7.4 6.1 6 5.9
Time domain (ms)
SDNN 107.4 6 37.5 107.6 6 36.7 110.4 6 37.4 95.7 6 39.3
SDANN 87.4 (25, 258) 88.0 (25, 258) 91.7 (27, 202) 69.3 (34, 147)
ASDNN 47.1 6 26.1 41.0 (12, 188) 42.5 (12, 195) 37.0 (18, 187)
RMSSD 24.6 (6, 267) 26.0 (6, 267) 22.8 (9, 259.5) 22.9 (8, 262)
Frequency domain (ms2)
VLF 1005.5 (36, 7532) 1019.0 (520, 5908) 1084.0 (36, 6252) 589.0 (162, 7532)
LF 310.0 (13, 11 977) 292.5 (13, 6688) 327.0 (16, 11 977) 241.0 (27, 7151)
HF 121.5 (5, 15 123) 141.0 (5, 11 247) 112.0 (16, 15 123) 102.0 (11, 11 445)
LF/HF ratio 2.5 (0.2, 14) 2.3 (0.2, 12) 2.9 (0.2, 14) 2.1 (0.3, 9)
Total power 1555.0 (118, 30 828) 1560.5 (132, 25 058) 1645.0 (118, 30 828) 1131.0 (306, 25 436)
aContinuous variables are reported as mean 6 SD for normally distributed variables and as median (min, max) for skewed variables. Significant
differences for CKD Stage 5 versus 3/4 are shown in bold (P < 0.05).
Fig. 2. Comparisons of HRV parameters among this CKD cohort (dark gray) and healthy controls [10] (white). Bars and whiskers represent the mean 6 SD.
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population [23]. Crude comparisons with data from pub-
lished literature from the USA revealed that the RRI-CKD
patients had lower HRV than subjects from the general
population, which is not surprising.
Recently, Mylonopoulou et al. [24] evaluated HRV in pa-
tients with diabetic and nondiabetic CKD Stage 4 (n ¼ 50)
and found that several time and frequency measures were
lower in diabetic versus nondiabetic patients. Patients were
excluded if they were on medications affecting ANS. These
patients were followed until they started dialysis and HRV
was repeated after 3 months of dialysis; some time domain
measures improved after dialysis. In our CKD cohort, we
found that the majority of time and frequency HRV measures
were lower in diabetics than nondiabetics. In addition, even
among nondiabetics, HRV was significantly lower than
healthy controls (P < 0.05, data not shown). We studied a
larger number of patients with CKD, reported on multiple
clinically relevant variables associated with low HRV includ-
ing medications affecting ANS and found associations of
HRV with clinical outcomes.
HRV as a predictor of clinical outcomes in CKD
In general, higher values of HRV were independently
associated with lower risk of all outcomes in this cohort.
Our findings indicate that similar to non-CKD populations,
low HRV appears to be a significant and independent marker
of adverse clinical outcomes, both with respect to CV events
(including the composite of CVD and mortality) [5, 6] and
possibly even progression to ESRD. Findings derived from
multivariable analysis suggest that the effect of HRV is in-
dependent of other clinical variables associated with in-
creased CVD risk, and given the strength of the
association (30–40% lower risk of, CVD event for each unit
higher HRV; Table 5) and its biological plausibility, likely
to be clinically important. Furthermore, in this patient pop-
ulation, certain clinical markers were associated with low
HRV (e.g. higher CRP, P, lower albumin, etc.). This would
suggest a potential link between these clinical variables and
autonomic dysregulation. These findings are relevant be-
cause the CKD population is at particularly high risk for
CVD and the study of novel CV risk factors is a research
priority that can assist in the discovery of newer targets for
therapy.
LF and LF/HF ratio were associated with improved out-
comes and may indicate better sympathovagal balance. LF
has been variably thought to represent sympathetic activity
by some and sympathovagal balance by others [5–7, 25,
26]. Though the physiological correlate of VLF is unclear
[thought to represent parasympathetic versus vasomotor
versus renin–angiotensin–aldosterone system (RAS)], it
has been shown to predict cardiac- and all-cause mortality
in the post-MI setting [6].
It is useful to compare our findings with studies on HRV
performed in patients on dialysis. Vita et al. [27] found that
LF was reduced in dialysis patients compared with controls.
Similar to our results, in patients on dialysis, reduced HRV
predicted cardiac [12] and all-cause and CV death [13].
In this study, higher HRV was associated with lower risk
of progression to ESRD; however, LF/HF ratio was the
only 24-h measure associated with risk to ESRD and this
association was weaker when LVMI was not included in
the multivariable ESRD model. There was significant cor-
relation observed between LVMI and HRV (LF/HF ratio),
which likely explains this relationship. Hence, the inde-
pendent effect of HRV in predicting ESRD cannot be
definitively concluded from our study. In patients with dia-
betes, autonomic dysfunction has been associated with in-
creased risk of progression of nephropathy [28, 29]. The
association of low HRV with increased risk of progression
to ESRD is biologically plausible. Renal failure is associ-
ated with increased sympathetic activity which has been
Table 4. Multiple linear regression models predicting 24-h HRV parameters (log transformed)












R2 ¼ 0.23 R2 ¼ 0.33 R2 ¼ 0.21 R2 ¼ 0.24 R2 ¼ 0.27
DM b ¼ 0.71*** b ¼ 0.51*** b ¼ 0.21*** b ¼ 0.46*** b ¼ 0.12**
Mean 24-h heart rate (b.p.m.) b ¼ 0.03*** b ¼ 0.03*** n/a b ¼ 0.03*** b ¼ 0.01***
Age n/a b ¼ 0.01*** b ¼ 0.01*** n/a b ¼ 0.003*
Gender: male n/a b ¼ 0.22* b ¼ 0.17** d n/a
Serum phosphorus (mg/dL) n/a n/a b ¼ 0.08* n/a n/a
CKD Stage 5 versus Stage 3/4 n/a b ¼ 0.42** c n/a b ¼ 0.15*
CRPa n/a n/a n/a b ¼ 0.13* n/a
High-density lipoprotein (mg/dL) b ¼ 0.02*** n/a n/a b ¼ 0.01*** n/a
Beta-blocker (Y/N) b b ¼ 0.26** n/a b ¼ 0.24* b ¼ 0.19***
LVMIa (g/m2) b ¼ 0.70** n/a n/a n/a n/a
Serum albumin (g/dL) n/a b ¼ 0.23* n/a n/a n/a
Urine albumin/creatinine ratio n/a n/a n/a n/a b ¼ 0.03**
Race: white n/a n/a n/a n/a b ¼ 0.11*
a Log-scale
bDue to the limitation on the samples size when LVMI was included, model selection without LVMI was performed. When LVMI was excluded, use of
beta-blocker was significantly associated with LF (b for beta-blocker ¼0.41, P ¼ 001; n ¼ 299).
cCompeting model: substituting CKD Stage 5 versus Stage 3/4 for phosphorus yields similar results (b for Stage 5 CKD ¼ 0.20, P ¼ 0.0099).
dCompeting model: substituting Gender for HDL yields similar results (b for gender ¼ 0.30, P ¼ 0.001; n = 285).
*P < 0.05, **P < 0.005, ***P < 0.0005.
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implicated in causing both vascular and glomerular injury
to the kidney [4]. Brotman et al. [30] have recently shown
that low HRV was significantly associated with increased
incidence of ESRD and CKD-related hospitalization in a
population-based cohort with mean eGFR of 93 mL/min/
1.73m2; in comparison, we have reported results on sub-
jects who already have moderately advanced CKD (mean
eGFR ¼ 28 mL/min/1.73m2).
Both autonomic withdrawal and high level of sympa-
thetic input can lead to decreased HRV [5]. In patients with
kidney disease, the pathogenesis of altered autonomic func-
tion is thought to be multifactorial. Increased sympathetic
activity can be attributed to (i) increased activity of RAS,
(ii) afferent signals released in response to ischemia from
diseased kidneys which in turn cause increased central
sympathetic outflow, (iii) peripheral denervation hypersen-
sitivity, (iv) decreased nitric oxide availability due to de-
creased nitric oxide (NO) synthase activity from increased
levels of NO inhibitors such as asymmetrical dimethylar-
ginine which are known to accumulate in renal failure, (v)
other contributing factors including diabetes, hypertension,
obesity, inflammation, smoking etc., which coexist in pa-
tients with CKD and can contribute to increased sympa-
thetic activity [2–4] and (vi) in addition, there is evidence
of decreased parasympathetic activity in patients with kid-
ney disease [27].
Despite its strengths, limitations of our study should be
acknowledged. This is an observational study and any
associations found do not prove causality. Our study was
based on HRV data collected at baseline in this CKD
cohort. We therefore cannot definitively comment on the
modification of risk of CVD or ESRD if HRV could be
improved, as that would require an interventional study.
GFR was estimated using the four-variable MDRD equa-
tion and not measured by more accurate isotope methods.
Serum creatinine was assayed by each institution’s own
laboratory, not centrally. We did not study healthy controls
directly, although we compare our findings with HRV
measures obtained in healthy controls in a US population.
The potential for ‘survival bias’ affecting our results
deserves mention, as patients enrolled in the cardiac sub-
study were, at least in part, survivors from among those
initially enrolled in the RRI-CKD study. However, this
survival bias should have led to the attenuation of the asso-
ciation between HRV and adverse outcomes, suggesting
that the documented association of adverse outcomes with
Fig. 3. Impact of HRV parameters on risk of CVD events. Hazard ratios and 95% confidence intervals associated with increases in HRV parameters, after
adjustment for age, history of CVD events, gender, serum phosphorus and albumin, are presented. Measures marked with an asterisk are plotted on the log scale.
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Table 5. (I) Cox regression models predicting time to (A) first CVD event (B) composite of CVD/death and (C) ESRD endpoints and (II) each HRV
measure was added to these ‘base’ models to further assess the relationship between HRV and outcomesa
(I) Base model (II) Base model 1 HRV parameter
Covariate HR (95% CI) for covariate HRV parameter HR (95% CI) for HRV
(A) First CVD event n ¼ 302, R2 ¼ 0.14 (A) First CVD event n ¼ 290 P-value R2
Age 1.04 (1.01–1.06)** LF/HF ratio 0.70 (0.48–1.02) 0.0608 0.15
Males 1.60 (0.87–2.94) LF (ln ms2) 0.69 (0.52–0.91)* 0.0077 0.16
Phosphorus (mg/dL) 1.53 (1.17–1.99)** VLF (ln ms2) 0.70 (0.51–0.98)* 0.0381 0.15
Albumin (g/dL) 0.35 (0.19–0.65)** ASDNN (ln ms) 0.51 (0.26–3.13) 0.0491 0.15
History of CVD 2.74 (1.47–5.13)** Total power (ln ms2) 0.69 (0.48–0.98)* 0.0358 0.15
(B) CVD or death n ¼ 304, R2 ¼ 0.14 (B) CVD or Death n ¼ 292 P-value R2
Age 1.04 (1.02–1.06)*** LF/HF ratio 0.62 (0.45–0.87) 0.0050 0.16
Males 1.55 (0.91–2.63) LF (ln ms2) 0.70 (0.55–0.90) 0.0053 0.16
Diabetes 1.86 (1.10–3.15)* VLF (ln ms2) 0.72 (0.54–0.96) 0.0263 0.15
Albumin (g/dL) 0.43 (0.24–0.75)** ASDNN (ln ms) 0.57 (0.31–1.03) 0.0641 0.15
History of CVD 1.79 (1.03–3.09)* Total power (ln ms2) 0.72 (0.52–0.98) 0.0387 0.15
(C) ESRD end point n ¼ 182, R2 ¼ 0.48 (C) ESRD end point n ¼ 174 P-value R2
Age 0.98 (0.96–1.00) LF/HF ratio 0.66 (0.44–0.98) 0.0372 0.50
Males 1.41 (0.78–2.56) LF (ln ms2) 0.93 (0.74–1.17) 0.5387 0.49
Ln (ACR) 1.21 (1.01–1.45)* VLF (ln ms2) 0.74 (0.54–1.03) 0.0768 0.50
Hemoglobin (g/dL) 0.77 (0.60–0.97)* ASDNN (ln ms) 0.83 (0.47–1.46) 0.5186 0.49
Ln (LVMI) (g/m2) 7.95 (3.14–20.13)*** Total power (ln ms2) 0.90 (0.67–1.21) 0.4978 0.49
eGFR (mL/min/1.73m2) 0.84 (0.80–0.88)***
aHazard ratios (HR) and 95% confidence intervals (CI) for selected HRV parameters (log transformed) are displayed above. Ratios for all HRV measures,
including day and night, are displayed in Supplementary Table C.
*P-value < 0.05, **P-value < 0.005, ***P-value < 0.0005.
Fig. 4. The cumulative probability of CVD events over time since Holter monitoring by LF/HF ratio (most predictive measure) above and below the
median. An LF/HF ratio below the median (<2.5) was associated with a significantly higher risk compared to an LF/HF ratio 2.5 (HR ¼ 2.52, P ¼
0.002). Plotted values were calculated based on Cox regression stratified by LF/HF ratio and adjusted for mean values of: age (60 years), phosphorus
(3.7), albumin (4.0), proportion with history of CVD (0.37) and proportion male (0.50).
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low HRV in this study is likely to have been even stronger
had the study measured HRV in all patients originally
enrolled in RRI-CKD. We did not have simultaneous meas-
urement of sympathetic activity (e.g. muscle sympathetic
activity) to determine if low HRV was associated with high
sympathetic activity. However, in comparison to healthy
controls from the literature, almost all HRV measures were
lower in our CKD cohort compared with healthy popula-
tion. In frequency domain analysis, LF (which is variably
thought to represent sympathetic activity versus sympatho-
vagal balance) as well as HF (measure of parasympathetic
activity) were reduced in CKD compared with healthy
population.
Summary and conclusions
Our study describes the spectrum of HRV obtained by 24-h
Holter monitoring in a prospective cohort of CKD (Stages
3–5) patients. We find several clinically important variables
including comorbidities and laboratory values which are
associated with lower HRV in this CKD population. Im-
portantly, lower HRV was independently associated with
higher risk of CVD, the composite of CVD/death and a
weaker association with ESRD. Our results suggest that
HRV has the potential to be a useful predictive tool for risk
stratification as well as an intermediate outcome for clinical
trials designed to test therapies that could eventually also
improve hard outcomes in patients with CKD. This study is
hypothesis generating at best due to its observational na-
ture, and we propose that more studies should be done to
further explore the practical utility of HRV as a clinical tool
to help identify those at higher CVD/ESRD risk in this
patient population. Further studies are also needed to in-
vestigate if HRV can be improved with certain classes of
medications and whether this improvement in HRV will
translate to improved CVD and other clinical outcomes.
Supplementary data
Supplementary Tables A–C are available online at http://
ndt.oxfordjournals.org.
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Abstract
Background. Hypogonadism or testosterone deficiency is
a prevalent condition in men with chronic kidney disease
(CKD). Testosterone stimulates erythropoiesis via produc-
tion of haematopoietic growth factors and possible im-
provement of iron bioavailability. We hypothesized that
testosterone deficiency predisposes to anaemia and reduced
responsiveness to erythropoiesis-stimulating agents (ESAs)
in CKD men.
Materials and methods. We studied associations be-
tween endogenous testosterone and haemoglobin in 239
ESA-naı̈ve nondialysed CKD Stages 1–5 male patients.
Additionally, we studied associations between endoge-
nous testosterone levels and ESA dose (U/kg/week) in
126 ESA-treated men undergoing haemodialysis (HD).
Results. Among ESA-naı̈ve males, patients with anaemia
presented lower testosterone values. Endogenous testos-
terone was negatively associated with haemoglobin levels
in uni- and multivariate models. Testosterone-deficient
patients (total testosterone <10 nmol/L) were 5.3 (95%
confidence interval 2.2–12.5) times more likely to be
anaemic (Hb < 13.0 g/dL) than testosterone-sufficient
patients. In ESA-treated men undergoing HD, higher
ESA doses (above the median value of 121 IU/kg body
weight/week) are associated with lower testosterone
levels and higher percentage of hypochromic red blood
cells (RBC). The inverse association between testosterone
levels and ESA doses persisted after multivariate adjust-
ment for age, sex hormone-binding globulin, comorbid-
ities, C-reactive protein and s-albumin but was lost after
further adjustment for iron medication and hypochromic
RBC.
Conclusions. Hypogonadism may be an additional cause
of anaemia and reduced ESA responsiveness in men with
CKD. Our results raise the possibility that restoration
of testosterone levels in hypogonadal CKD males may
translate into lower prevalence of anaemia and better
ESA responsiveness.
Keywords: androgens; chronic kidney disease; erythropoietin;
sex hormones
Introduction
Anaemia and hyporesponsiveness to erythropoiesis-
stimulating agents (ESA) are important phenomena
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